semaj83/ctmatch_classification huggingface dataset:
Patient description: A 25-year-old woman presents to the clinic complaining of prolonged fatigue. She denies difficulty sleeping and sleeps an average of 8 hours a night. She also notes hair loss, a change in her voice and weight gain during the previous 6 months. She complains of cold intolerance. On examination she has a prominent, soft, uniform anterior cervical mass at the midline.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Essential Tremor Subjects must be between the ages of 18 and 80 inclusive Each subject must have current manifestations of ET symptoms based on the Tremor Investigational Group (TRIG) for definite or probable ET Moderate or severe tremor in head or arms for at least 3 years duration No present causes of enhanced physiologic tremor No recent exposure to tremorogenic drugs or drug withdrawal states No direct or indirect trauma to the nervous system within 3 months preceding the onset of tremor No historic or clinical evidence of psychogenic tremor origin Subjects with a history of seizures are eligible Subjects must be in generally good health as evidenced by previous medical history and clinical examination Patients will be allowed to take Beta-blockers but will not be allowed to take any other medication for tremor (primidone, topiramate, benzodiazepines, etc.) An evening dose of a benzodiazepine to improve sleep is acceptable. They must have been on a stable dose of any existing beta-blocker for 4 weeks prior to entry into the study and will not be allowed to change the dose of that medication throughout the controlled portion of the study. Any medication discontinued during screening in order to comply with these must be stopped for 5 half-lives prior to study initiation  Patients do not meet TRIG for probable ET Subjects who are not able to abstain from alcohol for 24 hours prior to each evaluation Patients who can not maintain an identical dose of any medicine that may affect tremor during their entire study involvement Subjects who have exhibited any psychotic symptomatology Subjects who have known renal deficiencies Subjects who have been intolerant of pregabalin in the past Prior surgical treatment for tremor Patients currently taking more than a single drug for ET Patients taking anti-seizure medications Breast feeding or pregnant females
Patient description: A 25-year-old woman presents to the clinic complaining of prolonged fatigue. She denies difficulty sleeping and sleeps an average of 8 hours a night. She also notes hair loss, a change in her voice and weight gain during the previous 6 months. She complains of cold intolerance. On examination she has a prominent, soft, uniform anterior cervical mass at the midline.

Clinical trial eligibility criteria: eligible ages (years): 25.0-50.0,  Obesity Weight Gain Body mass index (BMI) 30-39.9 kg/m2 Age 25-50 years No more than 3 kg weight loss during past three months Negative pregnancy test at entry; women of childbearing potential may be enrolled if they have had a tubal ligation or use one of the following means of contraception: condom, diaphragm, oral or implanted contraceptives, or intrauterine device. Women in exclusive relationships with male partners who have had a successful vasectomy will not be required to use any additional means of birth control  BMI < 30 or >40 Type II diabetes requiring the use of any oral antidiabetic agent and/or insulin (because of confounding effects on body weight regulation) Adverse response to study foods (lactose intolerance, dairy intolerance, dairy allergy); this will be determined by self-report History or presence of significant metabolic disease which could impact on the results of the study (i.e. endocrine, hepatic, renal disease) History of eating disorder Presence of active gastrointestinal disorders such as malabsorption syndromes Pregnancy or lactation Use of obesity pharmacotherapeutic agents within the last 6 months Use of over-the-counter anti-obesity agents (e.g. those containing phenylpropanalamine, ephedrine and/or caffeine) within the last 6 months Recent (past 12 weeks) use of tobacco
Patient description: A 25-year-old woman presents to the clinic complaining of prolonged fatigue. She denies difficulty sleeping and sleeps an average of 8 hours a night. She also notes hair loss, a change in her voice and weight gain during the previous 6 months. She complains of cold intolerance. On examination she has a prominent, soft, uniform anterior cervical mass at the midline.

Clinical trial eligibility criteria: eligible ages (years): 18.0-48.0,  Hypothyroidism Premenopausal women with overt primary hypothyroidism (reduced T4 concentration accompanied by increased TSH concentration at the time of initial diagnosis) who did not receive thyroid hormones  Peri and postmenopause Pregnancy Major comorbidity Use of drugs that affect metabolism or bioavailability of thyroid hormones preparations
Patient description: A 25-year-old woman presents to the clinic complaining of prolonged fatigue. She denies difficulty sleeping and sleeps an average of 8 hours a night. She also notes hair loss, a change in her voice and weight gain during the previous 6 months. She complains of cold intolerance. On examination she has a prominent, soft, uniform anterior cervical mass at the midline.

Clinical trial eligibility criteria: eligible ages (years): 21.0-999.0,  Weight Loss Age range: 21 years and older Body mass index between 25.0-39.9 kg/m2 Weight stable (< 4.5 kg (~10 lbs) weight gain or loss within last 6 months) Body fat >25% (assessed by skinfold and plethysmography (if needed)) Non-smoking (within the last 6 months) Constant habitual activity patterns (within last 3 months) Clinically normal blood profiles (specifically, normal liver and kidney function; fasting blood glucose <110 mg/dl) Not taking medications known to influence appetite or metabolism Non-diabetic  Age: <21 years Body mass index: outside of the 25.0-39.9 kg/m2 range Gained or lost > 4.5 kg (10 lbs) within the last 6 months Body fat <25% as assessed by plethysmography Smoker (currently or within the last 6 months) Intermittently been involved in a diet and/or exercise program within the last 3 months Clinically abnormal blood profiles as identified by our study physician, Arthur Rosen, MD Taking medications (currently or within the last 3 months) known to influence appetite or metabolism Clinically diagnosed as diabetic Allergies to eggs
Patient description: A 25-year-old woman presents to the clinic complaining of prolonged fatigue. She denies difficulty sleeping and sleeps an average of 8 hours a night. She also notes hair loss, a change in her voice and weight gain during the previous 6 months. She complains of cold intolerance. On examination she has a prominent, soft, uniform anterior cervical mass at the midline.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Fibromyalgia Fibromyalgia using ACR diagnosis  Other confounding disease including other inflammatory disease, pain and depression
Patient description: A 25-year-old woman presents to the clinic complaining of prolonged fatigue. She denies difficulty sleeping and sleeps an average of 8 hours a night. She also notes hair loss, a change in her voice and weight gain during the previous 6 months. She complains of cold intolerance. On examination she has a prominent, soft, uniform anterior cervical mass at the midline.

Clinical trial eligibility criteria: eligible ages (years): 21.0-35.0,  Obesity Healthy normal and obese volunteers  serious medical or neurological condition
Patient description: A 25-year-old woman presents to the clinic complaining of prolonged fatigue. She denies difficulty sleeping and sleeps an average of 8 hours a night. She also notes hair loss, a change in her voice and weight gain during the previous 6 months. She complains of cold intolerance. On examination she has a prominent, soft, uniform anterior cervical mass at the midline.

Clinical trial eligibility criteria: eligible ages (years): 18.0-85.0,  Rheumatoid Arthritis Rheumatoid arthritis patients will meet American College of Rheumatology revised (Arnett, Edworthy et al. 1988). This requires at least four of the following seven 1) morning joint stiffness; 2) arthritis in 3 or more joint areas; 3) arthritis of hand joints; 4) symmetric arthritis; 5) rheumatoid nodules; 6) presence of serum rheumatoid factor and 7) changes on posteroanterior hand and wrist radiographs. In addition, 1-4 must be present for at least four weeks. Subjects must be between 18 and 85 years of age If rheumatoid arthritis patients are receiving treatment with traditional disease modifying antirheumatic drugs (DMARD), such as methotrexate, sulfasalazine or hydroxychloroquine, they must be on a stable regime for one month before study and stable throughout study If rheumatoid arthritis patients have received treatment with a TNF antagonist or other biologic medication, they must be drug free for greater than 3 months  Steroids Individuals currently taking greater than an equivalent of 10 mg of prednisone will be excluded given the potent anti-inflammatory effects of such medications Opioids Individuals using multiple daily dosage schedule of opioid agents such as oxycodone (Percocet), hydrocodone (Vicodin), morphine, Dilaudid will be excluded Co-morbid medical disorders the presence of active unstable and uncontrolled co-morbid medical conditions such as diabetes, cardiovascular diseases, and cancer will be exclusionary criteria. In particular, individuals with co-morbid inflammatory disorders such as Crohn's disease and ulcerative colitis and other autoimmune disorders will be excluded. Any uncontrolled medical condition that is deemed by the investigators to interfere with the proposed study procedures, or put the study participant at undue risk will also be considered exclusionary criteria Chronic infections individuals with chronic infections will also be excluded because of effects on immune markers measured in study Co-morbid pain disorders individuals with co-morbid pain disorders such as fibromyalgia will also be excluded. Individuals with fibromyalgia have been found to have sleep abnormalities as well as daytime fatigue and pain (Drewes 1999) and thus could confound findings
Patient description: A 25-year-old woman presents to the clinic complaining of prolonged fatigue. She denies difficulty sleeping and sleeps an average of 8 hours a night. She also notes hair loss, a change in her voice and weight gain during the previous 6 months. She complains of cold intolerance. On examination she has a prominent, soft, uniform anterior cervical mass at the midline.

Clinical trial eligibility criteria: eligible ages (years): 25.0-999.0,  Obesity Morbid Obesity Obese and morbidly obese women (BMI 30 years and older undergoing laparoscopic gastric bypass surgery Present with at least either metabolic syndrome or diabetes  Have smoked in the past 4 weeks Pregnant Allergic or intolerant to ingredients used in the study (e.g. soy and THIAA) There is a sound medical, psychiatric and/or social reason as determined by the Principal Investigator (PI) that makes the subject unsuitable for the study
Patient description: A 25-year-old woman presents to the clinic complaining of prolonged fatigue. She denies difficulty sleeping and sleeps an average of 8 hours a night. She also notes hair loss, a change in her voice and weight gain during the previous 6 months. She complains of cold intolerance. On examination she has a prominent, soft, uniform anterior cervical mass at the midline.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Neoplasms, Lung Carcinoma, Non-Small Cell Lung Drug Therapy Genes, EGFR Male and female patients aged over 18 years Histologically proven lung adenocarcinoma clinical stage IIIB/IV ECOG performance status 0-2 Had no prior anticancer agent, radiation or surgical therapy for lung adenocarcinoma At least one measurable lesion (according to Provision of written informed consent Life expectancy of at least 12 weeks  History of malignant disease Evidence of clinically active interstitial lung diseases (patients with chronic, stable, radiographic changes who are asymptomatic need not be excluded) Expected life expectancy less than 2 months As judged by the investigator, any evidence of severe or uncontrolled systemic disease (e.g. unstable or uncompensated respiratory, cardiac, hepatic, or renal disease) Aspartate aminotransferase (AST/SGOT) or alanine aminotransferase (ALT/SGPT) ≥ 2.5 x ULN if no demonstrable liver metastases (or >5 x in presence of liver metastases) Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the subject to participate in the study Pregnancy or breast-feeding women (women of child¬bearing potential). Women of childbearing potential must practice acceptable methods of birth control to prevent pregnancy
Patient description: A 25-year-old woman presents to the clinic complaining of prolonged fatigue. She denies difficulty sleeping and sleeps an average of 8 hours a night. She also notes hair loss, a change in her voice and weight gain during the previous 6 months. She complains of cold intolerance. On examination she has a prominent, soft, uniform anterior cervical mass at the midline.

Clinical trial eligibility criteria: eligible ages (years): 35.0-60.0,  Hypothyroidism Recently diagnosed hypothyroid subject (either during the period, or within the 6 previous months) for whom, data related to the diagnosis is available if the diagnosis was not carried out initially by the investigating doctor Subject, who has given his/her oral consent for participation  Subject included in clinical trial or having participated in a clinical trial during the last 3 months Subject presenting a major and objectifiable risk of not being able to follow-up until the next TSH level (moving, problems encountered during another study, pathology affecting the vital prognosis in the short-term) All contraindications to Lévothyrox
Patient description: A 25-year-old woman presents to the clinic complaining of prolonged fatigue. She denies difficulty sleeping and sleeps an average of 8 hours a night. She also notes hair loss, a change in her voice and weight gain during the previous 6 months. She complains of cold intolerance. On examination she has a prominent, soft, uniform anterior cervical mass at the midline.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Major Depressive Disorder Patients must be adult, diagnosed with major depressive disorder and treated with pharmacotherapy Physicians must be either a psychiatrist or a primary care physician, a prescriber of Pristiq, have at least 3 charts representing the 4 identified patient types, have been in clinical practice between 4 and 35 years, primarily office based (50%+), not participated in a research study relating to antidepressants or antidepressant therapy within the past month, not a consultant or have a professional relationship with a pharmaceutical company other than for clinical trials or speaking engagements, and not be employed by of affiliated with an advertising agency, market research company, or pharmaceutical company  Patients who have not been treated for depression
Patient description: A 25-year-old woman presents to the clinic complaining of prolonged fatigue. She denies difficulty sleeping and sleeps an average of 8 hours a night. She also notes hair loss, a change in her voice and weight gain during the previous 6 months. She complains of cold intolerance. On examination she has a prominent, soft, uniform anterior cervical mass at the midline.

Clinical trial eligibility criteria: eligible ages (years): 20.0-999.0,  AITd Patients With Different Polymorphisms Autoimmune thyroid patients patients who cut Nodular Goiter in Wanfang Hospital
Patient description: A 25-year-old woman presents to the clinic complaining of prolonged fatigue. She denies difficulty sleeping and sleeps an average of 8 hours a night. She also notes hair loss, a change in her voice and weight gain during the previous 6 months. She complains of cold intolerance. On examination she has a prominent, soft, uniform anterior cervical mass at the midline.

Clinical trial eligibility criteria: eligible ages (years): 18.0-90.0,  Central Hypothyroidism Clinical evidence of central hypothyroidism: status post pituitary surgery and/or radiotherapy plus laboratory documentation of central hypothyroidism, with or without concurrent hormonal deficiencies in other axes, such as ACTH, LH, FSH  Primary hypothyroidism
Patient description: A 25-year-old woman presents to the clinic complaining of prolonged fatigue. She denies difficulty sleeping and sleeps an average of 8 hours a night. She also notes hair loss, a change in her voice and weight gain during the previous 6 months. She complains of cold intolerance. On examination she has a prominent, soft, uniform anterior cervical mass at the midline.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Androgenetic Alopecia Male, age 18 to 70 year old, in general good health Exhibits male AGA based on a discernable hair loss in temple and vertex region rating Hamilton-Norwood Scale III vertex to VI (See Appendix 1) Subjects who give their consent to the study after thorough explanation and who personally signed and dated the informed consent document indicating that the subject, has been informed of all pertinent aspects of the trial Willing to maintain the same hairstyle, hair length and hair color throughout the study Subjects who are willing and able to comply with scheduled visits, treatment plan, mini-tattoo and other trial procedures Accepting the Information form plus accepting and signing the Informed Consent form  Known to be hypersensitive to minoxidil, hair dye (p-phenylenediamine), tattoo ink, fragrances, hair gel or any vehicle components Current or 4 weeks dated back use of medical shampoos or solutions which Ketoconazole or the like (e. g. Terzolin®) in the target region interfering with the CTM or examination method Current or 3 months dated back use of topical treatment in the target regions taken for more then 2 consecutive weeks interfering with the CTM (topical corticosteroids, aminexil, minoxidil, estrogens) Current or 3 months dated back use of systemic treatment (drugs or dietary supplement) taken for more than 2 consecutive weeks interfering with the CTM or examination method (beta blocker, cimetidine, diazoxide, isotretionin, corticosteroids, vitamin A intake above 10000 IU per day) Current or 12 months dated back use of Finasteride (Propecia®, FinaHair®, etc.), Dutasteride or a similar product Within past 12 months undergoing chemotherapy or receiving cytotoxic agents as well as radiation and/or laser/surgical therapy of the scalp Current or prior enrollment in any other investigational medication (drug) study within the 4 weeks prior to study initiation Presence of hair transplants, hair weaves or non-breathable wigs and hair bonding Current or 2 months dated back severe diet or presenting a history of eating disorder Any dermatological disorders of the scalp in the target region with the possibility of interfering with the CTM or examination method, such as fungal or bacterial infections, seborrheic dermatitis, psoriasis, eczema, folliculitis, scars or scalp atrophy
Patient description: A 25-year-old woman presents to the clinic complaining of prolonged fatigue. She denies difficulty sleeping and sleeps an average of 8 hours a night. She also notes hair loss, a change in her voice and weight gain during the previous 6 months. She complains of cold intolerance. On examination she has a prominent, soft, uniform anterior cervical mass at the midline.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Thyroiditis, Autoimmune adults 18-70 years of age having positive antibodies against thyroid peroxidase having sonographic evidence consistent with a diagnosis of Hashimoto's thyroiditis  having evidence of end-stage thyroiditis being a current smoker or smokeless tobacco user be taking systemic glucocorticoids, interferon-alpha, anti-CD20 antibody, or anti-CTLA-4 antibody be taking any medication for treatment of autoimmune thyroiditis other than L-thyroxine or equivalent
Patient description: A 25-year-old woman presents to the clinic complaining of prolonged fatigue. She denies difficulty sleeping and sleeps an average of 8 hours a night. She also notes hair loss, a change in her voice and weight gain during the previous 6 months. She complains of cold intolerance. On examination she has a prominent, soft, uniform anterior cervical mass at the midline.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Hypopituitarism All patients with pituitary hypopituitarism  Unavailability of data
Patient description: A 25-year-old woman presents to the clinic complaining of prolonged fatigue. She denies difficulty sleeping and sleeps an average of 8 hours a night. She also notes hair loss, a change in her voice and weight gain during the previous 6 months. She complains of cold intolerance. On examination she has a prominent, soft, uniform anterior cervical mass at the midline.

Clinical trial eligibility criteria: eligible ages (years): 0.5-1.5,  Down Syndrome patient with a karyotype demonstrating homogeneous, free or Robertsonian translocation trisomy 21 patient having undergone a cardiac ultrasound not demonstrating any severe heart disease patient aged 6 to 18 months at  congenital hypothyroidism hypothyroidism demonstrated by laboratory tests presenting or having presented hyperthyroidism presenting or having presented leukaemia presenting or having presented West syndrome or any other form of epilepsy or unstable neurological disease presenting or having presented signs of central nervous system distress: stroke, postoperative hypoxia, meningitis) presenting severe heart disease on cardiac ultrasound, with haemodynamic effects presenting non-controlled cardiac arrhythmia Apgar < 7 to 5 min at birth Gestational age < 245 days (35 weeks)
Patient description: A 25-year-old woman presents to the clinic complaining of prolonged fatigue. She denies difficulty sleeping and sleeps an average of 8 hours a night. She also notes hair loss, a change in her voice and weight gain during the previous 6 months. She complains of cold intolerance. On examination she has a prominent, soft, uniform anterior cervical mass at the midline.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Primary Hypothyroidism. Patients will be between the ages of 18 to 65 and will have been on levothyroxine for primary hypothyroidism for at least 6 months  Patients will be excluded if they have the following problems: pregnancy, plan for pregnancy in the next 12 months, cardiac disease, especially coronary artery disease, chronic obstructive lung disease, malabsorption disorder, gastrointestinal surgeries, significant renal or liver dysfunction, seizure disorders, thyroid and non-thyroid active cancers, uncontrolled psychosis, psychotropic medication use, steroid use, amiodarone, chemotherapy for cancer, iron supplement more than 325mg per day, carafate/ proton pump inhibitor use, cholestyramine use, and those with recent PCS orders who are expected to move out of the geographic area, age less than 18 years old or older than 65 years old Patients scheduled for deployment will be excluded